Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies

References

• Laporte R, Hui A, Laher I. Pharmacological modulation of sarcoplasmic reticulum function in smooth muscle. Pharmacol. Rev.56, 439–513 (2004).
   PubMed Web of Science ®Google Scholar
• Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev.84, 767–801 (2004).
   PubMed Web of Science ®Google Scholar
• Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev.81, 999–1030 (2001).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420, 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Thom T, Haase N, Rosamond W et al. Heart Disease and Stroke Statistics – 2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113, E85–E151 (2006).
   PubMed Web of Science ®Google Scholar
• Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle–brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch. Intern. Med.163, 1939–1942 (2003).
   PubMed Web of Science ®Google Scholar
• Simosa HF, Conte MS. Genetic therapy for vein bypass graft disease: current perspectives. Vascular12, 213–217 (2004).
   PubMedGoogle Scholar
• Woods TC, Marks AR. Drug-eluting stents. Ann. Rev. Med.55, 169–178 (2004).
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol.40, 2082–2089 (2002).
   PubMed Web of Science ®Google Scholar
• Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation97, 916–931 (1998).
   PubMed Web of Science ®Google Scholar
• Mohler ER III. Peripheral arterial disease: identification and implications. Arch. Intern. Med.163, 2306–2314 (2003).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med.8, 1249–1256 (2002).
   PubMed Web of Science ®Google Scholar
• Cai X, Freedman NJ. New therapeutic possibilities for vein graft disease in the post-edifoligide era. Future Cardiol.2, 493–501 (2006).
   PubMedGoogle Scholar
• Goldschmidt-Clermont PJ, Creager MA, Lorsordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation112, 3348–3353 (2005).
   PubMedGoogle Scholar
• Sata M, Saiura A, Kunisato A et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med.8, 403–409 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Sugiyama S, Aikawa M et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat. Med.7, 738–741 (2001).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat. Med.9, 653–660 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380, 439–442 (1996).
   PubMed Web of Science ®Google Scholar
• Gittenberger-de Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth muscle cell origin and its relation to heterogeneity in development and disease. Arterioscler. Thromb. Vasc. Biol.19, 1589–1594 (1999).
   PubMedGoogle Scholar
• Yoshida T, Owens GK. Molecular determinants of vascular smooth muscle cell diversity. Circ. Res.96, 280–291 (2005).
   PubMed Web of Science ®Google Scholar
• Kirby ML, Waldo KL. Neural crest and cardiovascular patterning. Circ. Res.77, 211–215 (1995).
   PubMed Web of Science ®Google Scholar
• Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development127, 1607–1616 (2000).
   PubMed Web of Science ®Google Scholar
• DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, Gittenberger-de Groot AC. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ. Res.80, 444–451 (1997).
   PubMed Web of Science ®Google Scholar
• Reese DE, Mikawa T, Bader DM. Development of the coronary vessel system. Circ. Res.91, 761–768 (2002).
   PubMedGoogle Scholar
• Domenga V, Fardoux P, Lacombe P et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev.18, 2730–2735 (2004).
   PubMed Web of Science ®Google Scholar
• Hao H, Gabbiani G, Bochaton-Piallat ML. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol.23, 1510–1520 (2003).
   PubMed Web of Science ®Google Scholar
• Frid MG, Aldashev AA, Dempsey EC, Stenmark KR. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities. Circ. Res.81, 940–952 (1997).
   PubMed Web of Science ®Google Scholar
• Benzakour O, Kanthou C, Kanse SM, Scully MF, Kakkar VV, Cooper DN. Evidence for cultured human vascular smooth muscle cell heterogeneity: isolation of clonal cells and study of their growth characteristics. Thromb. Haemost.75, 854–858 (1996).
   PubMedGoogle Scholar
• Li S, Fan YS, Chow LH et al. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res.89, 517–525 (2001).
   PubMedGoogle Scholar
• Bochaton-Piallat ML, Clowes AW, Clowes MM et al. Cultured arterial smooth muscle cells maintain distinct phenotypes when implanted into carotid artery. Arterioscler. Thromb. Vasc. Biol.21, 949–954 (2001).
   PubMedGoogle Scholar
• Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, Olson EN. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature428, 185–189 (2004).
   PubMed Web of Science ®Google Scholar
• Weiser-Evans MC, Schwartz PE, Grieshaber NA et al. Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ. Res.87, 608–615 (2000).
   PubMedGoogle Scholar
• Weiser-Evans MC, Quinn BE, Burkard MR, Stenmark KR. Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery smooth muscle cells after vascular injury. J. Cell Physiol.182, 12–23 (2000).
   PubMedGoogle Scholar
• Wenzlau JM, Garl PJ, Simpson P et al. Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development. Circ. Res.98, 846–855 (2006).
   PubMedGoogle Scholar
• van der Loop FT, Gabbiani G, Kohnen G, Ramaekers FC, van Eys GJ. Differentiation of smooth muscle cells in human blood vessels as defined by smoothelin, a novel marker for the contractile phenotype. Arterioscler. Thromb. Vasc. Biol.17, 665–671 (1997).
   PubMed Web of Science ®Google Scholar
• Feil R, Feil S, Hofmann F. A heretical view on the role of NO and cGMP in vascular proliferative diseases. Trends Mol. Med.11, 71–75 (2005).
   PubMed Web of Science ®Google Scholar
• Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Ann. Rev. Genomics Hum. Genet.5, 189–218 (2004).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352, 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang WD, Bai HZ, Sawa Y et al. Association of smooth muscle cell phenotypic modulation with extracellular matrix alterations during neointima formation in rabbit vein grafts. J. Vasc. Surg.30, 169–183 (1999).
   PubMedGoogle Scholar
• Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler. Thromb. Vasc. Biol.24, 1006–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Christen T, Verin V, Bochaton-Piallat M et al. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation103, 882–888 (2001).
   PubMed Web of Science ®Google Scholar
• Aikawa M, Kim HS, Kuro-o M et al. Phenotypic modulation of smooth muscle cells during progression of human atherosclerosis as determined by altered expression of myosin heavy chain isoforms. Ann. NY Acad. Sci.748, 578–585 (1995).
   PubMedGoogle Scholar
• Aikawa M, Yamaguchi H, Yazaki Y, Nagai R. Smooth muscle phenotypes in developing and atherosclerotic human arteries demonstrated by myosin expression. J. Atheroscler. Thromb.2, 14–23 (1995).
   PubMedGoogle Scholar
• Mulvihill ER, Jaeger J, Sengupta R et al. Atherosclerotic plaque smooth muscle cells have a distinct phenotype. Arterioscler. Thromb. Vasc. Biol.24, 1283–1289 (2004).
   PubMedGoogle Scholar
• Hao H, Gabbiani G, Camenzind E, Bacchetta M, Virmani R, Bochaton-Piallat ML. Phenotypic modulation of intima and media smooth muscle cells in fatal cases of coronary artery lesion. Arterioscler. Thromb. Vasc. Biol.26, 326–332 (2006).
   PubMed Web of Science ®Google Scholar
• Aikawa M, Sakomura Y, Ueda M et al. Redifferentiation of smooth muscle cells after coronary angioplasty determined via myosin heavy chain expression. Circulation96, 82–90 (1997).
   PubMedGoogle Scholar
• Liu C, Nath KA, Katusic ZS, Caplice NM. Smooth muscle progenitor cells in vascular disease. Trends Cardiovasc. Med.14, 288–293 (2004).
   PubMed Web of Science ®Google Scholar
• Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J. Vasc. Res.38, 113–119 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res.93, 783–790 (2003).
   PubMedGoogle Scholar
• Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler. Thromb. Vasc. Biol.24, 470–476 (2004).
   PubMedGoogle Scholar
• Hu Y, Mayr M, Metzler B, Erdel M, Davison F, Xu Q. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ. Res.91, E13–E20 (2002).
   PubMedGoogle Scholar
• Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J. Origin of neointimal endothelium and α-actin-positive smooth muscle cells in transplant arteriosclerosis. J. Clin. Invest.107, 1411–1422 (2001).
   PubMed Web of Science ®Google Scholar
• Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat. Med.7, 382–383 (2001).
   PubMed Web of Science ®Google Scholar
• Sata M. Molecular strategies to treat vascular diseases: circulating vascular progenitor cell as a potential target for prophylactic treatment of atherosclerosis. Circ. J67, 983–991 (2003).
   PubMed Web of Science ®Google Scholar
• Hillebrands JL, Onuta G, Rozing J. Role of progenitor cells in transplant arteriosclerosis. Trends Cardiovasc. Med.15, 1–8 (2005).
   PubMedGoogle Scholar
• Roberts N, Jahangiri M, Xu Q. Progenitor cells in vascular disease. J. Cell Mol. Med.9, 583–591 (2005).
   PubMed Web of Science ®Google Scholar
• Yamashita J, Itoh H, Hirashima M et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature408, 92–96 (2000).
   PubMed Web of Science ®Google Scholar
• Sainz J, Al Haj Zen A, Caligiuri G et al. Isolation of “side population” progenitor cells from healthy arteries of adult mice. Arterioscler. Thromb. Vasc. Biol.26, 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation106, 1199–1204 (2002).
   PubMed Web of Science ®Google Scholar
• Kashiwakura Y, Katoh Y, Tamayose K et al. Isolation of bone marrow stromal cell-derived smooth muscle cells by a human SM22α promoter: in vitro differentiation of putative smooth muscle progenitor cells of bone marrow. Circulation107, 2078–2081 (2003).
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Kugiyama K, Nakamura S et al. Characterization of smooth muscle-like cells in circulating human peripheral blood. Atherosclerosis187, 351–362 (2006).
   PubMedGoogle Scholar
• Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J. Am. Coll. Cardiol.43, 18–23 (2004).
   PubMed Web of Science ®Google Scholar
• Minami E, Laflamme MA, Saffitz JE, Murry CE. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation112, 2951–2958 (2005).
   PubMed Web of Science ®Google Scholar
• Glaser R, Lu MM, Narula N, Epstein JA. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation106, 17–19 (2002).
   PubMed Web of Science ®Google Scholar
• Quaini F, Urbanek K, Beltrami AP et al. Chimerism of the transplanted heart. N. Engl. J. Med.346, 5–15 (2002).
   PubMed Web of Science ®Google Scholar
• Caplice NM, Bunch TJ, Stalboerger PG et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc. Natl Acad. Sci. USA100, 4754–4759 (2003).
   PubMedGoogle Scholar
• Li J, Han X, Jiang J et al. Vascular smooth muscle cells of recipient origin mediate intimal expansion after aortic allotransplantation in mice. Am. J. Pathol.158, 1943–1947 (2001).
   PubMed Web of Science ®Google Scholar
• Hu Y, Davison F, Ludewig B et al. Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circulation106, 1834–1839 (2002).
   PubMed Web of Science ®Google Scholar
• Cooley BC. Murine model of neointimal formation and stenosis in vein grafts. Arterioscler. Thromb. Vasc. Biol.24, 1180–1185 (2004).
   PubMedGoogle Scholar
• Sata M, Tanaka K, Nagai R. Origin of smooth muscle progenitor cells: different conclusions from different models. Circulation107, E106–E107 (2003).
   PubMedGoogle Scholar
• van der Meer J, Hillege HL, Kootstra GJ et al. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Lancet342, 257–264 (1993).
   PubMed Web of Science ®Google Scholar
• de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet357, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Lincoff AM, Kereiakes DJ et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med.113, 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N. Engl. J. Med.336, 153–162 (1997).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med.335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Sianos G et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J. Am. Coll. Cardiol.44, 1363–1367 (2004).
   PubMed Web of Science ®Google Scholar
• Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation111, 2257–2273 (2005).
   PubMed Web of Science ®Google Scholar
• Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation111, 926–931 (2005).
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation103, 192–195 (2001).
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Sousa AG et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation107, 381–383 (2003).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Fajadet J, Morice MC, Bode C et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation111, 1040–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR, Jr. et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de novo Native Coronary Lesions (SIRIUS) trial. J. Am. Coll. Cardiol.47, 1350–1355 (2006).
   PubMed Web of Science ®Google Scholar
• Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J. Am. Coll. Cardiol.47, 1356–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Wessely R, Schomig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J. Am. Coll. Cardiol.47, 708–714 (2006).
   PubMed Web of Science ®Google Scholar
• Patterson C, Mapera S, Li HH et al. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler. Thromb. Vasc. Biol.26, 1473–1480 (2006).
   PubMedGoogle Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48, 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Jimenez-Quevedo P, Sabate M, Angiolillo DJ et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J. Am. Coll. Cardiol.47, 2172–2179 (2006).
   PubMed Web of Science ®Google Scholar
• Ge L, Iakovou I, Sangiorgi GM et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J. Am. Coll. Cardiol.45, 989–994 (2005).
   PubMedGoogle Scholar
• Schachner T, Zou Y, Oberhuber A et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann. Thorac. Surg.77, 1580–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Masaki T, Rathi R, Zentner G et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int.66, 2061–2069 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. Arch. Biochem. Biophys.412, 157–169 (2003).
   PubMed Web of Science ®Google Scholar
• Mann MJ. Transcription factor decoys: a new model for disease intervention. Ann. NY Acad. Sci.1058, 128–139 (2005).
   PubMed Web of Science ®Google Scholar
• Miyake T, Aoki M, Shiraya S et al. Inhibitory effects of NFκB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J. Mol. Cell Cardiol.41(3), 431–440 (2006).
   PubMed Web of Science ®Google Scholar
• Kume M, Komori K, Matsumoto T et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation105, 1226–1232 (2002).
   PubMedGoogle Scholar
• Ehsan A, Mann MJ, Dell’Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J. Thorac. Cardiovasc. Surg.121, 714–722 (2001).
   PubMed Web of Science ®Google Scholar
• Morishita R, Gibbons GH, Horiuchi M et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl Acad. Sci. USA92, 5855–5859 (1995).
   PubMed Web of Science ®Google Scholar
• Mann MJ, Whittemore AD, Donaldson MC et al.Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet354, 1493–1498 (1999).
   PubMed Web of Science ®Google Scholar
• Grube E. PRoject of Ex-vivo Vein graft ENgineering via Transfection (PREVENT) II trial. Presented at The Annual American Heart Association Scientific Sessions, Anaheim, CA, USA November 11–14, 2001
   Google Scholar
• Conte MS, Bandyk DF, Clowes AW et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg.43, 742–751 (2006).
   PubMed Web of Science ®Google Scholar
• Alexander JH, Hafley G, Harrington RA et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA294, 2446–2454 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Hagen PO, Kisslo J, Peppel K, Freedman NJ. Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. J. Vasc. Surg.36, 824–832 (2002).
   PubMedGoogle Scholar
• Sano H, Sudo T, Yokode M et al. Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation103, 2955–2960 (2001).
   PubMed Web of Science ®Google Scholar
• Raj T, Kanellakis P, Pomilio G, Jennings G, Bobik A, Agrotis A. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol.26, 1845–1851 (2006).
   PubMed Web of Science ®Google Scholar
• Hart CE, Kraiss LW, Vergel S et al. PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon. Circulation99, 564–569 (1999).
   PubMed Web of Science ®Google Scholar
• Agrotis A, Kanellakis P, Kostolias G et al. Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J. Biol. Chem.279, 42221–42229 (2004).
   PubMed Web of Science ®Google Scholar
• Davies MG, Owens EL, Mason DP et al. Effect of platelet-derived growth factor receptor-a and -b blockade on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ. Res.86, 779–786 (2000).
   PubMedGoogle Scholar
• Levitzki A, Mishani E. Tyrphostins and Other Tyrosine Kinase Inhibitors. Ann. Rev. Biochem.75, 93–109 (2006).
   PubMed Web of Science ®Google Scholar
• Levitzki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc. Res.65, 581–586 (2005).
   PubMed Web of Science ®Google Scholar
• Banai S, Chorny M, Gertz SD et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials26, 451–461 (2005).
   PubMed Web of Science ®Google Scholar
• Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ. Res.96, 172–179 (2005).
   PubMedGoogle Scholar
• O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.348, 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Myllarniemi M, Frosen J, Calderon Ramirez LG, Buchdunger E, Lemstrom K, Hayry P. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther.13, 159–168 (1999).
   PubMed Web of Science ®Google Scholar
• Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science300, 329–332 (2003).
   PubMed Web of Science ®Google Scholar
• Lassila M, Allen TJ, Cao Z et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol.24, 935–942 (2004).
   PubMed Web of Science ®Google Scholar
• Zohlnhofer D, Hausleiter J, Kastrati A et al. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J. Am. Coll. Cardiol.46, 1999–2003 (2005).
   PubMedGoogle Scholar
• Hausleiter J, Kastrati A, Mehilli J et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation110, 790–795 (2004).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension46, 7–18 (2005).
   PubMed Web of Science ®Google Scholar
• Dashwood MR, Savage K, Dooley A, Shi-Wen X, Abraham DJ, Souza DS. Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. Ann. Thorac. Surg.80, 939–944 (2005).
   PubMedGoogle Scholar
• Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension45, 321–325 (2005).
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest.108, 391–397 (2001).
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim TY, Cho HJ et al. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents. J. Am. Coll. Cardiol.48, 366–374 (2006).
   PubMed Web of Science ®Google Scholar
• Mayr U, Zou Y, Zhang Z, Dietrich H, Hu Y, Xu Q. Accelerated arteriosclerosis of vein grafts in inducible no synthase-/- mice is related to decreased endothelial progenitor cell repair. Circ. Res.98, 412–440 (2006).
   PubMed Web of Science ®Google Scholar
• Walter DH, Cejna M, Diaz-Sandoval L et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation110, 36–45 (2004).
   PubMed Web of Science ®Google Scholar
• Blindt R, Vogt F, Astafieva I et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol.47, 1786–1795 (2006).
   PubMed Web of Science ®Google Scholar
• Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol.26, 257–266 (2006).
   PubMed Web of Science ®Google Scholar
• Cai X, Lytton J. The cation/Ca2+ exchanger superfamily: phylogenetic analysis and structural implications. Mol. Biol. Evol.21, 1692–1703 (2004).
   PubMedGoogle Scholar
• Wamhoff BR, Bowles DK, Owens GK. Excitation-transcription coupling in arterial smooth muscle. Circ. Res.98, 868–878 (2006).
   PubMedGoogle Scholar
• Barlow CA, Rose P, Pulver-Kaste RA, Lounsbury KM. Excitation-transcription coupling in smooth muscle. J. Physiol.570, 59–64 (2006).
   PubMedGoogle Scholar
• Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M. A calmodulin-binding site on cyclin E mediates Ca2+-sensitive G1/s transitions in vascular smooth muscle cells. Circ. Res.98, 1273–1281 (2006).
   PubMed Web of Science ®Google Scholar
• Mann KM, Ray JL, Moon ES, Sass KM, Benson MR. Calcineurin initiates smooth muscle differentiation in neural crest stem cells. J. Cell Biol.165, 483–491 (2004).
   PubMedGoogle Scholar
• Wamhoff BR, Bowles DK, McDonald OG et al. L-type voltage-gated Ca2+ channels modulate expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-dependent mechanism. Circ. Res.95, 406–414 (2004).
   PubMedGoogle Scholar
• Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol.23, 2155–2163 (2003).
   PubMed Web of Science ®Google Scholar
• Arakawa E, Hasegawa K. Benidipine, a calcium channel blocker, regulates proliferation and phenotype of vascular smooth muscle cells. J. Pharmacol. Sci.100, 149–156 (2006).
   PubMedGoogle Scholar
• Kohler R, Wulff H, Eichler I et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation108, 1119–1125 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar B, Dreja K, Shah S et al. Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ. Res.98, 557–563 (2006).
   PubMedGoogle Scholar
• Lipskaia L, del Monte F, Capiod T et al. Sarco/endoplasmic reticulum Ca2+- ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ. Res.97, 488–495 (2005).
   PubMed Web of Science ®Google Scholar
• Hata JA, Petrofski JA, Schroder JN et al. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J. Thorac. Cardiovasc. Surg.129, 1405–1413 (2005).
   PubMedGoogle Scholar
• Huang J, Niu XL, Pippen AM, Annex BH, Kontos CD. Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol.25, 354–358 (2005).
   PubMedGoogle Scholar
• Barbato JE, Tzeng E. iNOS gene transfer for graft disease. Trends Cardiovasc. Med.14, 267–272 (2004).
   PubMedGoogle Scholar
• Johnson TW, Wu YX, Herdeg C et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol.25, 754–759 (2005).
   PubMedGoogle Scholar
• Zhang L, Peppel K, Brian L, Chien L, Freedman NJ. Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler. Thromb. Vasc. Biol.24, 2277–2283 (2004).
   PubMed Web of Science ®Google Scholar
• Zou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q. Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ. Res.86, 434–440. (2000).
   PubMed Web of Science ®Google Scholar
• Schepers A, Eefting D, Bonta PI et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol.26, 2063–2069 (2006).
   PubMed Web of Science ®Google Scholar
• George SJ, Beeching CA. Cadherin:catenin complex: A novel regulator of vascular smooth muscle cell behaviour. Atherosclerosis188, 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Leppanen O, Rutanen J, Hiltunen MO et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation109, 1140–1146 (2004).
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Lieberman J. Knocking down Disease with siRNAs. Cell126, 231–235 (2006).
   PubMed Web of Science ®Google Scholar
• Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J. Am. Coll. Cardiol.48, 227–235 (2006).
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, Vivanco F, Michel JB, Meilhac O, Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc. Res.72, 18–29 (2006).
   PubMed Web of Science ®Google Scholar